{"id":80812,"date":"2025-02-24T09:03:16","date_gmt":"2025-02-24T09:03:16","guid":{"rendered":"https:\/\/www.cofb.org\/?p=80812"},"modified":"2025-02-27T10:19:29","modified_gmt":"2025-02-27T10:19:29","slug":"farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/","title":{"rendered":"Farmac\u00e8utics i farmac\u00e8utiques de diferents \u00e0mbits s\u2019actualitzen en l’abordatge de l’asma greu"},"content":{"rendered":"\n

El passat 5 de febrer, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB)<\/strong>, juntament amb la Sociedad Espa\u00f1ola de Farmacia Hospitalaria (SEFH)<\/a>, va organitzar la formaci\u00f3 \u201cActualitzaci\u00f3 en asma greu\u201d<\/strong>, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC)<\/a> i el patrocini d\u2019AstraZeneca<\/a>. La jornada, adre\u00e7ada a farmac\u00e8utics i farmac\u00e8utiques d\u2019hospital, d\u2019atenci\u00f3 prim\u00e0ria i comunit\u00e0ries<\/strong>, va ser coordinada pels vocals del COFB d\u2019Hospitals, d\u2019Atenci\u00f3 Prim\u00e0ria i Oficina de Farm\u00e0cia, David Conde, Cristina Morales i Merc\u00e8 Barau<\/strong>; i la vocal del SEFH, Aurora Fern\u00e1ndez<\/strong>.<\/p>\n\n\n\n

Els objectius <\/strong>de la jornada van ser con\u00e8ixer les caracter\u00edstiques de l’asma greu i el seu impacte<\/strong>, actualitzar la gesti\u00f3<\/strong> i el tractament<\/strong>, revisar aspectes d’atenci\u00f3 farmac\u00e8utica<\/strong> relacionats amb la dispensaci\u00f3 i el seguiment i exposar l’abordatge multidisciplinari del pacient amb asma greu<\/strong>.<\/p>\n\n\n\n

La formaci\u00f3 va ser presentada per Aurora Fern\u00e1ndez<\/strong>, delegada de la SEFH a Catalunya, que va explicar que aquesta acci\u00f3 formativa s\u2019ha impulsat per abordar de manera transversal l\u2019atenci\u00f3 farmac\u00e8utica als pacients amb asma i asma greus, entre tots els nivells assistencials<\/strong>. \u201cAquesta jornada vol posar el focus en les estrat\u00e8gies per actualitzar els tractaments en l\u2019asma, els programes d\u2019atenci\u00f3 farmac\u00e8utica per a la millora de l\u2019adher\u00e8ncia als tractaments, i establir sinergies entre la farm\u00e0cia hospital\u00e0ria, farm\u00e0cia d\u2019atenci\u00f3 prim\u00e0ria i farm\u00e0cia comunit\u00e0ria per a impulsar iniciatives d\u2019atenci\u00f3 farmac\u00e8utica coordinades<\/strong>\u201d, va declarar. <\/p>\n\n\n\n

\"\"<\/a>
Aurora Fern\u00e1ndez (esquerra) i Cristina Morales (dreta) en un moment de la seva presentaci\u00f3. <\/figcaption><\/figure>\n\n\n\n

Per part seva, Cristina Morales<\/strong>, vocal d\u2019Atenci\u00f3 Prim\u00e0ria del COFB i coordinadora de la formaci\u00f3, va afirmar que, la participaci\u00f3 de la vocalia d\u2019hospitals, farm\u00e0cia comunit\u00e0ria i d\u2019atenci\u00f3 prim\u00e0ria en l\u2019organitzaci\u00f3 del curs, \u201cs\u2019ha considerat una oportunitat per donar visibilitat de com \u00e9s de fonamental el treball col\u00b7laboratiu entre els farmac\u00e8utics d\u2019aquests nivells assistencials<\/strong> en l\u2019acompanyament al pacient en l\u2019abordatge del tractament farmacol\u00f2gic de la seva patologia, en aquest cas, de l\u2019asma\u201d.<\/p>\n\n\n\n

Definici\u00f3 de criteris per a l\u2019asma greu i l\u2019asma greu no controlada i opcions terap\u00e8utiques i innovaci\u00f3<\/strong><\/h2>\n\n\n\n

A continuaci\u00f3, va intervenir el pneum\u00f2leg, cap del Servei de Pneumologia, Hospital Universitari Vall d\u2019Hebron, Xavier Mu\u00f1oz, <\/strong>que va definir l\u2019asma bronquial<\/strong> com a \u201cmalaltia inflamat\u00f2ria cr\u00f2nica de les vies respirat\u00f2ries, en la patog\u00e8nia de les quals intervenen diverses c\u00e8l\u00b7lules i mediadors d’inflamaci\u00f3, condicionada en part per factors gen\u00e8tics<\/strong> i que cursa amb hiperresposta bronquial (HRB)<\/strong> i una obstrucci\u00f3 variable del flux aeri<\/strong>, totalment o parcialment reversible, sigui farmacol\u00f2gicament o espont\u00e0niament\u201d.<\/p>\n\n\n\n

\"Xavier<\/a>
Xavier Mu\u00f1oz en un moment de la seva exposici\u00f3. <\/figcaption><\/figure>\n\n\n\n

Mu\u00f1oz va indicar quina \u00e9s la prevalen\u00e7a<\/strong> d\u2019aquesta patologia, com confirmar el diagn\u00f2stic<\/strong> i optimitzar el tractament<\/strong>, aix\u00ed com els factors del pacient<\/strong> segons l\u2019adhesi\u00f3, la t\u00e8cnica inhalat\u00f2ria i les comorbiditats. Tanmateix, va explicar quines exposicions ambientals<\/strong> poden afectar (h\u00e0bit tab\u00e0quic, exposici\u00f3 d\u2019al\u00b7l\u00e8rgens, contaminaci\u00f3 ambiental, agents ocupacionals i f\u00e0rmacs) i va fer menci\u00f3 al fenotip del pacient.<\/p>\n\n\n\n

Per la seva banda, Cristina D\u00edez<\/strong>, farmac\u00e8utica hospital\u00e0ria de l\u2019\u00c0rea d\u2019Atenci\u00f3 Farmac\u00e8utica al Pacient Ambulatori de l\u2019Hospital Universitari Doctor Josep Trueta va abordar el maneig integral del pacient asm\u00e0tic, posant \u00e8mfasi en els fenotips del pacient amb diagn\u00f2stic d\u2019asma greu i les alternatives terap\u00e8utiques disponibles que s\u2019empren en la pr\u00e0ctica cl\u00ednica dins de l\u2019\u00e0mbit hospitalari<\/strong>, tot destacant la import\u00e0ncia d\u2019una gesti\u00f3 adequada i personalitzada per a optimitzar els resultats en els pacients m\u00e9s complexos.<\/p>\n\n\n\n

\"Cristina<\/a>
Cristina D\u00edez impartint la seva presentaci\u00f3 sobre el maneig integral del pacient asm\u00e0tic. <\/figcaption><\/figure>\n\n\n\n

A m\u00e9s, va presentar les recomanacions terap\u00e8utiques<\/strong> basades en les guies cl\u00edniques actuals per al tractament de l\u2019asma greu no controlat, orientant sobre com seleccionar el tractament biol\u00f2gic m\u00e9s adequat per cada pacient, en funci\u00f3 dels objectius terap\u00e8utics plantejats.<\/p>\n\n\n\n

Seguidament, va intervenir Assumpta Ricart<\/strong>, gerent de Processos Integrats de Salut de l’\u00c0rea Assistencial del CatSalut, que exposar quin \u00e9s el viatge del pacient asm\u00e0tic en el sistema sanitari<\/strong>, en qu\u00e8 cal con\u00e8ixer les necessitats, planificar, finan\u00e7ar i avaluar.<\/strong><\/p>\n\n\n\n

\"\"<\/a>
Assumpta Ricart durant la seva exposici\u00f3. <\/figcaption><\/figure>\n\n\n\n

Atenci\u00f3 farmac\u00e8utica i continu\u00eftat assistencial<\/strong><\/h2>\n\n\n\n

En relaci\u00f3 amb l\u2019atenci\u00f3 farmac\u00e8utica i la continu\u00eftat assistencial, Merc\u00e8 Barau<\/strong>, vocal d\u2019Oficina de Farm\u00e0cia del COFB i coordinadora de la formaci\u00f3, va explicar que davant una dispensaci\u00f3 d\u2019un inhalador, \u201cel farmac\u00e8utic no sols ha de vetllar per la seva correcta dispensaci\u00f3, assegurant una administraci\u00f3 ben feta per part del pacient, tamb\u00e9 ha de conscienciar a l\u2019usuari a retornar els inhaladors usats o caducats a les farm\u00e0cies <\/strong>de la comunitat per a una eliminaci\u00f3 adequada, alhora que amb tota probabilitat amb aquesta acci\u00f3 s\u2019ajudar\u00e0 a reduir les dispensacions innecess\u00e0ries. D\u2019aquesta manera no nom\u00e9s es dona un suport als pacients per millorar la seva qualitat pulmonar, sin\u00f3 que alhora es redueixen les emissions provocades pels inhaladors millorant l\u2019aire que tots respirem\u201d.<\/p>\n\n\n\n

\"\"<\/a>
Merc\u00e8 Barau en un moment de la seva intervenci\u00f3 en format online<\/em>. <\/figcaption><\/figure>\n\n\n\n



Durant aquesta taula sobre l\u2019atenci\u00f3 farmac\u00e8utica i la continu\u00eftat assistencial, Esther Pastor<\/strong>, farmac\u00e8utica d\u2019Atenci\u00f3 Prim\u00e0ria, va destacar la import\u00e0ncia de la continu\u00eftat assistencial<\/strong> per \u201cevitar duplicitats, millorar l\u2019efectivitat i l\u2019efici\u00e8ncia de les actuacions, disminuir els riscos sanitaris i augmentar la satisfacci\u00f3 del pacient\u201d<\/strong>.  <\/p>\n\n\n\n

\"\"<\/a>
Esther Pastor durant la seva presentaci\u00f3.<\/figcaption><\/figure>\n\n\n\n

Aix\u00ed doncs, va destacar alguns elements clau per a la continu\u00eftat assistencial<\/strong>, va recordar que l\u2019atenci\u00f3 prim\u00e0ria \u201c\u00e9s clau per al diagn\u00f2stic preco\u00e7 i el control i seguiment de la malaltia\u201d<\/strong> i va exposar com els farmac\u00e8utics i farmac\u00e8utiques comunit\u00e0ries, hospital\u00e0ries i d\u2019atenci\u00f3 prim\u00e0ria poden col\u00b7laborar en l\u2019abordatge del pacient amb asma.<\/p>\n\n\n\n

Marta Roig<\/strong>, farmac\u00e8utica comunit\u00e0ria i titular d\u2019oficina de Farm\u00e0cia a Sentmenat i professora de pr\u00e0ctiques tutelades a la UB, va detallar la import\u00e0ncia que el pacient rebi la mateixa informaci\u00f3 des de tots els \u00e0mbits professionals<\/strong> (especialista, hospital, atenci\u00f3 prim\u00e0ria i farm\u00e0cia comunit\u00e0ria). <\/p>\n\n\n\n

\"\"<\/a>
Marta Roig impartint la seva exposici\u00f3.<\/figcaption><\/figure>\n\n\n\n

\u201cEl pacient ha de percebre l\u2019asma greu com una malaltia cr\u00f2nica amb un tractament de manteniment i un de rescat. En la farm\u00e0cia comunit\u00e0ria tamb\u00e9 intervenim en l\u2019adher\u00e8ncia al tractament, explicant l\u2019\u00fas i t\u00e8cnica dels inhaladors i registrant la nostra actuaci\u00f3 farmac\u00e8utica al Consell de Col.legis de Farmac\u00e8utics de Catalunya<\/strong>\u201d, va declarar.<\/p>\n\n\n\n

En darrer lloc, Jorge del Estal<\/strong>, va recordar que, \u201cdes de la farm\u00e0cia hospital\u00e0ria podem contribuir en el maneig del pacient asm\u00e0tic a trav\u00e9s d\u2019una intervenci\u00f3 farmacoterap\u00e8utica adequada, centrada en l\u2019optimitzaci\u00f3 de la medicaci\u00f3 i el monitoratge constant de l\u2019adher\u00e8ncia i resultats en salut, contribuint directament a millorar el control de la malaltia<\/strong>. La dispensaci\u00f3 personalitzada i l\u2019acompanyament constant al pacient en el seu tractament farmacol\u00f2gic poden reduir les exacerbacions i les hospitalitzacions”. <\/p>\n\n\n\n

\"\"<\/a>
Jorge del Estal en un moment de la seva presentaci\u00f3. <\/figcaption><\/figure>\n\n\n\n

“D\u2019altra banda, la introducci\u00f3 de la visi\u00f3 del farmac\u00e8utic hospitalari en l\u2019equip multidisciplinari pot oferir una visi\u00f3 que afavoreixi l\u2019atenci\u00f3 integral i que atengui totes les necessitats del pacient asm\u00e0tic\u201d, va assegurar.<\/p>\n\n\n\n

Coorganitza:<\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/div>\n\n\n\n

Col\u00b7labora:<\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/div>\n\n\n\n
<\/div>\n\n\n\n

Patrocina:<\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

El passat 5 de febrer, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB), juntament amb la Sociedad Espa\u00f1ola de Farmacia Hospitalaria (SEFH), va organitzar la formaci\u00f3 \u201cActualitzaci\u00f3 en asma greu\u201d, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC) i el patrocini d\u2019AstraZeneca. La jornada, adre\u00e7ada a farmac\u00e8utics i […]<\/p>\n","protected":false},"author":3,"featured_media":80816,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[23,57],"tags":[211,487,64,938,18,19,53,69,480,70,76],"class_list":["post-80812","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-destacats","category-mon-collegial","tag-asma","tag-asma-greu","tag-atencio-farmaceutica","tag-atencio-primaria","tag-cofb","tag-collegi-de-farmaceutics-de-barcelona","tag-farmaceutics","tag-farmacia-comunitaria","tag-farmacia-hospitalaria","tag-formacio","tag-oficina-de-farmacia"],"yoast_head":"\nFarmac\u00e8utics i farmac\u00e8utiques de diferents \u00e0mbits s\u2019actualitzen en l'abordatge de l'asma greu - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"El passat 5 de febrer, el COFB, juntament amb la Sociedad Espa\u00f1ola de Farmacia Hospitalaria (SEFH), la formaci\u00f3 \u201cActualitzaci\u00f3 en asma greu.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cofb.org\/ca\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Farmac\u00e8utics i farmac\u00e8utiques de diferents \u00e0mbits s\u2019actualitzen en l'abordatge de l'asma greu - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El passat 5 de febrer, el COFB, juntament amb la Sociedad Espa\u00f1ola de Farmacia Hospitalaria (SEFH), la formaci\u00f3 \u201cActualitzaci\u00f3 en asma greu.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cofb.org\/ca\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-24T09:03:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-27T10:19:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Berta Mart\u00ednez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Berta Mart\u00ednez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/\"},\"author\":{\"name\":\"Berta Mart\u00ednez\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063\"},\"headline\":\"Farmac\u00e8utics i farmac\u00e8utiques de diferents \u00e0mbits s\u2019actualitzen en l’abordatge de l’asma greu\",\"datePublished\":\"2025-02-24T09:03:16+00:00\",\"dateModified\":\"2025-02-27T10:19:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/\"},\"wordCount\":1329,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-scaled.jpg\",\"keywords\":[\"asma\",\"asma greu\",\"Atenci\u00f3 farmac\u00e8utica\",\"Atenci\u00f3 prim\u00e0ria\",\"COFB\",\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"farmac\u00e8utics\",\"farm\u00e0cia comunit\u00e0ria\",\"farm\u00e0cia hospital\u00e0ria\",\"Formaci\u00f3\",\"Oficina de farm\u00e0cia\"],\"articleSection\":[\"Destacats\",\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/\",\"url\":\"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/\",\"name\":\"Farmac\u00e8utics i farmac\u00e8utiques de diferents \u00e0mbits s\u2019actualitzen en l'abordatge de l'asma greu - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-scaled.jpg\",\"datePublished\":\"2025-02-24T09:03:16+00:00\",\"dateModified\":\"2025-02-27T10:19:29+00:00\",\"description\":\"El passat 5 de febrer, el COFB, juntament amb la Sociedad Espa\u00f1ola de Farmacia Hospitalaria (SEFH), la formaci\u00f3 \u201cActualitzaci\u00f3 en asma greu.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/#primaryimage\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-scaled.jpg\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-scaled.jpg\",\"width\":2560,\"height\":1440},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Farmac\u00e8utics i farmac\u00e8utiques de diferents \u00e0mbits s\u2019actualitzen en l’abordatge de l’asma greu\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063\",\"name\":\"Berta Mart\u00ednez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g\",\"caption\":\"Berta Mart\u00ednez\"},\"url\":\"https:\/\/www.cofb.org\/ca\/author\/bmartinez\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Farmac\u00e8utics i farmac\u00e8utiques de diferents \u00e0mbits s\u2019actualitzen en l'abordatge de l'asma greu - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"El passat 5 de febrer, el COFB, juntament amb la Sociedad Espa\u00f1ola de Farmacia Hospitalaria (SEFH), la formaci\u00f3 \u201cActualitzaci\u00f3 en asma greu.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cofb.org\/ca\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/","og_locale":"ca_ES","og_type":"article","og_title":"Farmac\u00e8utics i farmac\u00e8utiques de diferents \u00e0mbits s\u2019actualitzen en l'abordatge de l'asma greu - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"El passat 5 de febrer, el COFB, juntament amb la Sociedad Espa\u00f1ola de Farmacia Hospitalaria (SEFH), la formaci\u00f3 \u201cActualitzaci\u00f3 en asma greu.","og_url":"https:\/\/www.cofb.org\/ca\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2025-02-24T09:03:16+00:00","article_modified_time":"2025-02-27T10:19:29+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-scaled.jpg","type":"image\/jpeg"}],"author":"Berta Mart\u00ednez","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"Berta Mart\u00ednez","Temps estimat de lectura":"9 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/#article","isPartOf":{"@id":"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/"},"author":{"name":"Berta Mart\u00ednez","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063"},"headline":"Farmac\u00e8utics i farmac\u00e8utiques de diferents \u00e0mbits s\u2019actualitzen en l’abordatge de l’asma greu","datePublished":"2025-02-24T09:03:16+00:00","dateModified":"2025-02-27T10:19:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/"},"wordCount":1329,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-scaled.jpg","keywords":["asma","asma greu","Atenci\u00f3 farmac\u00e8utica","Atenci\u00f3 prim\u00e0ria","COFB","Col\u00b7legi de Farmac\u00e8utics de Barcelona","farmac\u00e8utics","farm\u00e0cia comunit\u00e0ria","farm\u00e0cia hospital\u00e0ria","Formaci\u00f3","Oficina de farm\u00e0cia"],"articleSection":["Destacats","M\u00f3n col\u00b7legial"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/","url":"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/","name":"Farmac\u00e8utics i farmac\u00e8utiques de diferents \u00e0mbits s\u2019actualitzen en l'abordatge de l'asma greu - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/#primaryimage"},"image":{"@id":"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-scaled.jpg","datePublished":"2025-02-24T09:03:16+00:00","dateModified":"2025-02-27T10:19:29+00:00","description":"El passat 5 de febrer, el COFB, juntament amb la Sociedad Espa\u00f1ola de Farmacia Hospitalaria (SEFH), la formaci\u00f3 \u201cActualitzaci\u00f3 en asma greu.","breadcrumb":{"@id":"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/#primaryimage","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-scaled.jpg","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-scaled.jpg","width":2560,"height":1440},{"@type":"BreadcrumbList","@id":"https:\/\/www.cofb.org\/2025\/02\/24\/farmaceutics-i-farmaceutiques-de-diferents-ambits-sactualitzen-en-labordatge-de-lasma-greu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Farmac\u00e8utics i farmac\u00e8utiques de diferents \u00e0mbits s\u2019actualitzen en l’abordatge de l’asma greu"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063","name":"Berta Mart\u00ednez","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g","caption":"Berta Mart\u00ednez"},"url":"https:\/\/www.cofb.org\/ca\/author\/bmartinez\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-scaled.jpg",2560,1440,false],"thumbnail":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-150x150.jpg",150,150,true],"medium":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-300x169.jpg",300,169,true],"medium_large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-768x432.jpg",768,432,true],"large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-1024x576.jpg",1024,576,true],"1536x1536":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-1536x864.jpg",1536,864,true],"2048x2048":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-2048x1152.jpg",2048,1152,true],"trp-custom-language-flag":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/02\/COFB_ASMA-GREU_24022025_0-18x10.jpg",18,10,true]},"uagb_author_info":{"display_name":"Berta Mart\u00ednez","author_link":"https:\/\/www.cofb.org\/ca\/author\/bmartinez\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat 5 de febrer, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB), juntament amb la Sociedad Espa\u00f1ola de Farmacia Hospitalaria (SEFH), va organitzar la formaci\u00f3 \u201cActualitzaci\u00f3 en asma greu\u201d, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC) i el patrocini d\u2019AstraZeneca. La jornada, adre\u00e7ada a farmac\u00e8utics i […]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/80812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=80812"}],"version-history":[{"count":23,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/80812\/revisions"}],"predecessor-version":[{"id":80873,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/80812\/revisions\/80873"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media\/80816"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=80812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=80812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=80812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}